| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 126 | 2026 | 2326 | 12.010 |
Why?
|
| Stroke Volume | 32 | 2026 | 535 | 5.180 |
Why?
|
| Neoplasms | 32 | 2026 | 2985 | 3.450 |
Why?
|
| Cardiology | 24 | 2025 | 514 | 2.930 |
Why?
|
| Myocarditis | 12 | 2024 | 132 | 2.910 |
Why?
|
| Cardiotoxicity | 17 | 2026 | 48 | 2.790 |
Why?
|
| Cardiovascular Diseases | 27 | 2026 | 2101 | 2.690 |
Why?
|
| Obesity | 16 | 2025 | 2384 | 2.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 12 | 2019 | 214 | 1.950 |
Why?
|
| Atrial Fibrillation | 8 | 2023 | 737 | 1.870 |
Why?
|
| Hospitalization | 23 | 2026 | 1939 | 1.790 |
Why?
|
| Ventricular Function, Left | 12 | 2026 | 546 | 1.760 |
Why?
|
| Antineoplastic Agents | 11 | 2026 | 1804 | 1.680 |
Why?
|
| Cardiomyopathies | 10 | 2026 | 520 | 1.670 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2024 | 1444 | 1.670 |
Why?
|
| Comorbidity | 14 | 2025 | 1583 | 1.600 |
Why?
|
| Humans | 227 | 2026 | 130555 | 1.540 |
Why?
|
| Natriuretic Peptide, Brain | 11 | 2021 | 325 | 1.510 |
Why?
|
| Medical Oncology | 8 | 2026 | 242 | 1.450 |
Why?
|
| Heart Diseases | 7 | 2026 | 501 | 1.450 |
Why?
|
| Amyloidosis | 5 | 2026 | 70 | 1.430 |
Why?
|
| Aged | 93 | 2026 | 20899 | 1.390 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2016 | 134 | 1.320 |
Why?
|
| Molecular Targeted Therapy | 2 | 2026 | 384 | 1.320 |
Why?
|
| Kidney Diseases | 4 | 2024 | 471 | 1.250 |
Why?
|
| American Heart Association | 22 | 2026 | 340 | 1.180 |
Why?
|
| Defibrillators, Implantable | 3 | 2026 | 214 | 1.140 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2024 | 365 | 1.140 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2018 | 44 | 1.110 |
Why?
|
| Precision Medicine | 3 | 2026 | 385 | 1.100 |
Why?
|
| Risk Assessment | 18 | 2026 | 3678 | 1.050 |
Why?
|
| Catheter Ablation | 2 | 2023 | 321 | 1.040 |
Why?
|
| Middle Aged | 87 | 2026 | 28415 | 0.980 |
Why?
|
| Risk Factors | 47 | 2026 | 10967 | 0.960 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2019 | 216 | 0.960 |
Why?
|
| Pacemaker, Artificial | 2 | 2025 | 194 | 0.960 |
Why?
|
| Male | 117 | 2026 | 64534 | 0.940 |
Why?
|
| United States | 57 | 2026 | 11883 | 0.890 |
Why?
|
| Spironolactone | 3 | 2015 | 19 | 0.880 |
Why?
|
| Echocardiography | 7 | 2026 | 1131 | 0.880 |
Why?
|
| Thrombosis | 3 | 2026 | 500 | 0.880 |
Why?
|
| Radiotherapy | 1 | 2025 | 120 | 0.870 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2025 | 152 | 0.830 |
Why?
|
| Female | 109 | 2026 | 70425 | 0.820 |
Why?
|
| Heart | 8 | 2025 | 660 | 0.820 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 846 | 0.810 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 39 | 0.810 |
Why?
|
| Acute Coronary Syndrome | 4 | 2022 | 246 | 0.810 |
Why?
|
| Body Mass Index | 10 | 2025 | 1679 | 0.810 |
Why?
|
| Radiation Injuries | 4 | 2026 | 141 | 0.810 |
Why?
|
| Registries | 10 | 2026 | 1614 | 0.800 |
Why?
|
| Ambulatory Care | 8 | 2018 | 401 | 0.790 |
Why?
|
| Guideline Adherence | 4 | 2021 | 388 | 0.770 |
Why?
|
| Clinical Trials as Topic | 8 | 2026 | 1127 | 0.770 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2023 | 25 | 0.770 |
Why?
|
| Coronary Artery Disease | 7 | 2025 | 893 | 0.740 |
Why?
|
| Atherosclerosis | 7 | 2023 | 947 | 0.730 |
Why?
|
| Cardiomyopathy, Hypertrophic | 5 | 2021 | 161 | 0.730 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2020 | 302 | 0.730 |
Why?
|
| Retrospective Studies | 48 | 2026 | 17557 | 0.720 |
Why?
|
| Renin-Angiotensin System | 5 | 2019 | 104 | 0.720 |
Why?
|
| Biomarkers | 21 | 2026 | 3386 | 0.690 |
Why?
|
| Cardiovascular System | 4 | 2023 | 98 | 0.670 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2021 | 26 | 0.660 |
Why?
|
| Hypoglycemic Agents | 5 | 2024 | 477 | 0.660 |
Why?
|
| Patient Readmission | 8 | 2025 | 435 | 0.650 |
Why?
|
| Coronavirus | 1 | 2020 | 28 | 0.650 |
Why?
|
| Prognosis | 24 | 2025 | 4867 | 0.640 |
Why?
|
| Quality of Health Care | 3 | 2021 | 408 | 0.640 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2025 | 355 | 0.620 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 951 | 0.610 |
Why?
|
| Cellular Senescence | 3 | 2026 | 217 | 0.590 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 1408 | 0.580 |
Why?
|
| Hospitals, Veterans | 4 | 2020 | 337 | 0.570 |
Why?
|
| Diuretics | 8 | 2016 | 157 | 0.570 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 126 | 0.560 |
Why?
|
| Endpoint Determination | 4 | 2026 | 56 | 0.550 |
Why?
|
| Quality of Life | 5 | 2021 | 2074 | 0.550 |
Why?
|
| Myocardial Infarction | 6 | 2020 | 1001 | 0.540 |
Why?
|
| Incidence | 15 | 2025 | 3320 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 8 | 2026 | 1288 | 0.530 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 6800 | 0.520 |
Why?
|
| Societies, Medical | 5 | 2025 | 789 | 0.520 |
Why?
|
| Iron | 1 | 2020 | 305 | 0.520 |
Why?
|
| Leptin | 2 | 2025 | 216 | 0.520 |
Why?
|
| Lung Neoplasms | 5 | 2026 | 1547 | 0.520 |
Why?
|
| Diabetes Mellitus | 6 | 2019 | 891 | 0.520 |
Why?
|
| Follow-Up Studies | 21 | 2026 | 5164 | 0.520 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 456 | 0.510 |
Why?
|
| Inpatients | 2 | 2021 | 559 | 0.510 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 5 | 2015 | 34 | 0.510 |
Why?
|
| Coronary Disease | 3 | 2022 | 627 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2009 | 1272 | 0.500 |
Why?
|
| Cytokines | 11 | 2023 | 1343 | 0.480 |
Why?
|
| Prevalence | 13 | 2025 | 2688 | 0.480 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2016 | 11 | 0.480 |
Why?
|
| Cohort Studies | 18 | 2021 | 5049 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 351 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 363 | 0.460 |
Why?
|
| Troponin T | 4 | 2025 | 255 | 0.450 |
Why?
|
| Piperazines | 5 | 2015 | 269 | 0.450 |
Why?
|
| Treatment Outcome | 36 | 2025 | 12865 | 0.440 |
Why?
|
| Heart-Assist Devices | 6 | 2023 | 1014 | 0.440 |
Why?
|
| Peptide Fragments | 5 | 2021 | 688 | 0.430 |
Why?
|
| Valine | 4 | 2011 | 110 | 0.420 |
Why?
|
| Tetrazoles | 4 | 2011 | 71 | 0.420 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 231 | 0.420 |
Why?
|
| Cardiovascular Agents | 4 | 2016 | 88 | 0.410 |
Why?
|
| Cardio-Renal Syndrome | 3 | 2025 | 23 | 0.410 |
Why?
|
| Receptors, Cytokine | 4 | 2011 | 66 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2011 | 637 | 0.390 |
Why?
|
| Cerebrovascular Disorders | 3 | 2026 | 112 | 0.390 |
Why?
|
| Hyponatremia | 1 | 2014 | 72 | 0.390 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2026 | 150 | 0.390 |
Why?
|
| Drug Monitoring | 1 | 2016 | 287 | 0.380 |
Why?
|
| Thromboembolism | 2 | 2023 | 94 | 0.380 |
Why?
|
| Double-Blind Method | 13 | 2016 | 1621 | 0.380 |
Why?
|
| Outpatients | 2 | 2014 | 263 | 0.380 |
Why?
|
| Survival Rate | 8 | 2019 | 2114 | 0.380 |
Why?
|
| Sodium | 1 | 2014 | 278 | 0.380 |
Why?
|
| Myositis | 3 | 2024 | 105 | 0.380 |
Why?
|
| Vasodilator Agents | 4 | 2015 | 198 | 0.370 |
Why?
|
| Sarcoma | 2 | 2026 | 218 | 0.370 |
Why?
|
| Weight Loss | 4 | 2025 | 533 | 0.360 |
Why?
|
| Acute Disease | 7 | 2024 | 1154 | 0.360 |
Why?
|
| Veterans | 5 | 2016 | 1753 | 0.360 |
Why?
|
| Inflammation | 3 | 2025 | 1485 | 0.350 |
Why?
|
| Time Factors | 17 | 2026 | 6215 | 0.340 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2019 | 276 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 746 | 0.340 |
Why?
|
| Survival Analysis | 8 | 2018 | 1484 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2025 | 774 | 0.330 |
Why?
|
| Exercise Tolerance | 5 | 2015 | 91 | 0.330 |
Why?
|
| Coronary Artery Bypass | 3 | 2015 | 515 | 0.330 |
Why?
|
| Metabolic Syndrome | 3 | 2025 | 365 | 0.320 |
Why?
|
| Patient Care Management | 2 | 2020 | 61 | 0.320 |
Why?
|
| Research Report | 5 | 2022 | 73 | 0.320 |
Why?
|
| Cardiotonic Agents | 3 | 2016 | 141 | 0.310 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 237 | 0.300 |
Why?
|
| Predictive Value of Tests | 11 | 2026 | 2294 | 0.300 |
Why?
|
| Overweight | 2 | 2024 | 376 | 0.300 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 3031 | 0.290 |
Why?
|
| Sulfones | 3 | 2013 | 72 | 0.290 |
Why?
|
| Hospital Mortality | 7 | 2025 | 1060 | 0.290 |
Why?
|
| Myocardial Ischemia | 3 | 2008 | 309 | 0.280 |
Why?
|
| Metformin | 1 | 2010 | 171 | 0.280 |
Why?
|
| Adult | 24 | 2026 | 31157 | 0.280 |
Why?
|
| Blood Pressure | 8 | 2021 | 1342 | 0.270 |
Why?
|
| Hyperlipidemias | 2 | 2022 | 186 | 0.270 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2026 | 12 | 0.270 |
Why?
|
| Breast Neoplasms | 3 | 2026 | 2602 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor | 6 | 2003 | 73 | 0.270 |
Why?
|
| Prospective Studies | 17 | 2026 | 6438 | 0.260 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2026 | 233 | 0.260 |
Why?
|
| Research Design | 4 | 2012 | 712 | 0.260 |
Why?
|
| Drug Administration Schedule | 7 | 2012 | 723 | 0.260 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 42 | 0.250 |
Why?
|
| Electrocardiography | 4 | 2021 | 975 | 0.250 |
Why?
|
| Anti-Obesity Agents | 2 | 2025 | 47 | 0.250 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 81 | 0.250 |
Why?
|
| Digoxin | 2 | 2021 | 37 | 0.250 |
Why?
|
| Glomerular Filtration Rate | 7 | 2020 | 568 | 0.250 |
Why?
|
| Patient Selection | 5 | 2020 | 725 | 0.250 |
Why?
|
| Chronic Disease | 5 | 2023 | 1240 | 0.250 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2026 | 19 | 0.240 |
Why?
|
| Heart Rate | 4 | 2021 | 574 | 0.240 |
Why?
|
| Hemodynamics | 6 | 2021 | 809 | 0.240 |
Why?
|
| Nurse Practitioners | 2 | 2018 | 50 | 0.240 |
Why?
|
| Sex Factors | 8 | 2020 | 1340 | 0.240 |
Why?
|
| Digitoxin | 1 | 2026 | 13 | 0.240 |
Why?
|
| Anthracyclines | 1 | 2026 | 47 | 0.240 |
Why?
|
| Depressive Disorder | 1 | 2009 | 460 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2026 | 484 | 0.240 |
Why?
|
| Age Factors | 8 | 2018 | 2830 | 0.230 |
Why?
|
| Physician Assistants | 2 | 2018 | 81 | 0.230 |
Why?
|
| Renal Dialysis | 4 | 2020 | 949 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2023 | 11 | 0.230 |
Why?
|
| Ventricular Dysfunction | 1 | 2005 | 24 | 0.220 |
Why?
|
| Endocarditis, Non-Infective | 1 | 2025 | 2 | 0.220 |
Why?
|
| Hypertension | 7 | 2019 | 1347 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 290 | 0.220 |
Why?
|
| Equipment Failure | 1 | 2025 | 124 | 0.220 |
Why?
|
| Proportional Hazards Models | 6 | 2014 | 1391 | 0.220 |
Why?
|
| Myocardium | 4 | 2020 | 859 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2026 | 1610 | 0.220 |
Why?
|
| Mortality | 4 | 2024 | 261 | 0.220 |
Why?
|
| Heart Neoplasms | 1 | 2026 | 108 | 0.220 |
Why?
|
| Kidney Transplantation | 3 | 2019 | 557 | 0.220 |
Why?
|
| Cancer Survivors | 2 | 2025 | 274 | 0.220 |
Why?
|
| Stroke | 2 | 2017 | 1060 | 0.220 |
Why?
|
| Vascular Calcification | 1 | 2025 | 69 | 0.210 |
Why?
|
| Vitamin K | 2 | 2023 | 35 | 0.210 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 104 | 0.210 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2024 | 2 | 0.210 |
Why?
|
| Midodrine | 1 | 2024 | 3 | 0.210 |
Why?
|
| Hypotension, Orthostatic | 1 | 2024 | 20 | 0.210 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 104 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2025 | 101 | 0.210 |
Why?
|
| Evidence-Based Medicine | 7 | 2021 | 640 | 0.210 |
Why?
|
| Captopril | 1 | 2003 | 23 | 0.210 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 12 | 0.200 |
Why?
|
| Artificial Intelligence | 2 | 2026 | 351 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2026 | 223 | 0.200 |
Why?
|
| Pericarditis | 1 | 2024 | 43 | 0.200 |
Why?
|
| Dopamine | 2 | 2016 | 252 | 0.200 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 425 | 0.200 |
Why?
|
| Quinolines | 2 | 2001 | 115 | 0.200 |
Why?
|
| Anticoagulants | 3 | 2025 | 602 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2025 | 298 | 0.200 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2026 | 485 | 0.200 |
Why?
|
| Cardiologists | 1 | 2023 | 26 | 0.200 |
Why?
|
| Consensus | 6 | 2023 | 517 | 0.200 |
Why?
|
| Endothelium, Vascular | 3 | 2015 | 467 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2025 | 150 | 0.190 |
Why?
|
| Anxiety Disorders | 1 | 2009 | 726 | 0.190 |
Why?
|
| Assisted Circulation | 1 | 2023 | 23 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2015 | 298 | 0.190 |
Why?
|
| Endothelial Cells | 1 | 2026 | 520 | 0.190 |
Why?
|
| Heart Transplantation | 4 | 2023 | 837 | 0.190 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 290 | 0.180 |
Why?
|
| Meta-Analysis as Topic | 1 | 2023 | 169 | 0.180 |
Why?
|
| Cystatin C | 4 | 2016 | 73 | 0.180 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 166 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 306 | 0.180 |
Why?
|
| Random Allocation | 1 | 2003 | 415 | 0.180 |
Why?
|
| Vinca Alkaloids | 1 | 2021 | 2 | 0.180 |
Why?
|
| Heart Valve Diseases | 2 | 2021 | 165 | 0.180 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 700 | 0.180 |
Why?
|
| Lymphoma | 1 | 2025 | 327 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2026 | 420 | 0.180 |
Why?
|
| Health Services Research | 1 | 2003 | 178 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2016 | 56 | 0.170 |
Why?
|
| Taxoids | 1 | 2021 | 73 | 0.170 |
Why?
|
| Bisoprolol | 1 | 2021 | 7 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 60 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 62 | 0.170 |
Why?
|
| Lung Transplantation | 2 | 2023 | 352 | 0.170 |
Why?
|
| Heart Ventricles | 1 | 2026 | 759 | 0.170 |
Why?
|
| ROC Curve | 3 | 2025 | 611 | 0.170 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 151 | 0.170 |
Why?
|
| Interleukin-6 | 5 | 2011 | 412 | 0.170 |
Why?
|
| Aortic Diseases | 1 | 2023 | 187 | 0.170 |
Why?
|
| Weight Gain | 1 | 2023 | 383 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 154 | 0.170 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 190 | 0.170 |
Why?
|
| Heart Valves | 1 | 2021 | 52 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2024 | 406 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 150 | 0.170 |
Why?
|
| Organs at Risk | 3 | 2025 | 48 | 0.170 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 31 | 0.170 |
Why?
|
| Administration, Oral | 1 | 2023 | 709 | 0.160 |
Why?
|
| Radiation, Ionizing | 1 | 2020 | 38 | 0.160 |
Why?
|
| Erythropoietin | 1 | 2021 | 102 | 0.160 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 39 | 0.160 |
Why?
|
| Valsartan | 4 | 2011 | 26 | 0.160 |
Why?
|
| Glucosides | 1 | 2020 | 54 | 0.160 |
Why?
|
| Veterans Health | 2 | 2019 | 170 | 0.160 |
Why?
|
| Telemetry | 1 | 2020 | 22 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 937 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 142 | 0.160 |
Why?
|
| Logistic Models | 5 | 2016 | 1793 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 77 | 0.160 |
Why?
|
| Diastole | 2 | 2014 | 181 | 0.150 |
Why?
|
| Physicians | 2 | 2017 | 636 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 265 | 0.150 |
Why?
|
| Disease Management | 2 | 2021 | 555 | 0.150 |
Why?
|
| Home Care Services | 1 | 2020 | 70 | 0.150 |
Why?
|
| Losartan | 2 | 2011 | 36 | 0.150 |
Why?
|
| Biopsy | 2 | 2021 | 1244 | 0.150 |
Why?
|
| Animals | 11 | 2026 | 33856 | 0.150 |
Why?
|
| Doxorubicin | 3 | 2026 | 290 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 252 | 0.150 |
Why?
|
| Kidney | 3 | 2016 | 1280 | 0.150 |
Why?
|
| Radiotherapy Dosage | 3 | 2025 | 217 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2023 | 489 | 0.150 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.150 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 88 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 304 | 0.140 |
Why?
|
| Cachexia | 1 | 2019 | 57 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 500 | 0.140 |
Why?
|
| Thinness | 1 | 2019 | 71 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2021 | 394 | 0.140 |
Why?
|
| Advisory Committees | 1 | 2019 | 148 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 314 | 0.140 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 121 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 47 | 0.140 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 127 | 0.140 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 118 | 0.130 |
Why?
|
| Protein Precursors | 2 | 2021 | 139 | 0.130 |
Why?
|
| Semantics | 1 | 2018 | 47 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1332 | 0.130 |
Why?
|
| Procollagen | 2 | 2014 | 14 | 0.130 |
Why?
|
| Anemia | 1 | 2021 | 352 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2019 | 216 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2018 | 58 | 0.130 |
Why?
|
| Aspirin | 2 | 2018 | 214 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 282 | 0.130 |
Why?
|
| Confidence Intervals | 4 | 2015 | 270 | 0.130 |
Why?
|
| Ventricular Remodeling | 4 | 2012 | 154 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2023 | 889 | 0.120 |
Why?
|
| Coronary Vessels | 2 | 2025 | 525 | 0.120 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 106 | 0.120 |
Why?
|
| Echocardiography, Doppler | 2 | 2014 | 159 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 1071 | 0.120 |
Why?
|
| Urination | 1 | 2016 | 23 | 0.120 |
Why?
|
| Pandemics | 2 | 2021 | 1157 | 0.120 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2026 | 6 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 793 | 0.120 |
Why?
|
| Machine Learning | 1 | 2020 | 381 | 0.120 |
Why?
|
| Patient Discharge | 4 | 2020 | 516 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 384 | 0.120 |
Why?
|
| Texas | 7 | 2021 | 3648 | 0.110 |
Why?
|
| Cocaine | 1 | 2017 | 209 | 0.110 |
Why?
|
| Cause of Death | 2 | 2017 | 502 | 0.110 |
Why?
|
| Myocardial Contraction | 3 | 2015 | 243 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2025 | 3355 | 0.110 |
Why?
|
| Hematology | 2 | 2026 | 42 | 0.110 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 39 | 0.110 |
Why?
|
| Scleroderma, Systemic | 1 | 1996 | 117 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1277 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2025 | 1231 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2085 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 198 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 1 | 2017 | 205 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 1167 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2015 | 39 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 89 | 0.110 |
Why?
|
| Allopurinol | 1 | 2015 | 79 | 0.100 |
Why?
|
| Football | 1 | 2014 | 38 | 0.100 |
Why?
|
| Anthropometry | 1 | 2014 | 187 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2026 | 123 | 0.100 |
Why?
|
| Collagen Type I | 1 | 2014 | 110 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2016 | 1210 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 107 | 0.100 |
Why?
|
| Natriuretic Agents | 1 | 2013 | 28 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2016 | 268 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 112 | 0.100 |
Why?
|
| Sildenafil Citrate | 4 | 2015 | 56 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 100 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 144 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2016 | 293 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2015 | 182 | 0.100 |
Why?
|
| Renal Insufficiency | 2 | 2006 | 257 | 0.100 |
Why?
|
| Purines | 4 | 2015 | 115 | 0.100 |
Why?
|
| Calcinosis | 1 | 2014 | 179 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 627 | 0.100 |
Why?
|
| Ultrafiltration | 1 | 2012 | 12 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2009 | 713 | 0.100 |
Why?
|
| Natriuretic Peptides | 1 | 2012 | 9 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 1375 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 228 | 0.090 |
Why?
|
| Heart Failure, Diastolic | 1 | 2012 | 10 | 0.090 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 292 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 338 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 508 | 0.090 |
Why?
|
| Sex Distribution | 3 | 2015 | 319 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 173 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 324 | 0.090 |
Why?
|
| Reference Values | 2 | 2018 | 675 | 0.090 |
Why?
|
| Propanolamines | 1 | 2011 | 18 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2012 | 19 | 0.090 |
Why?
|
| Carbazoles | 1 | 2011 | 30 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2019 | 1060 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 448 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 298 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2001 | 40 | 0.090 |
Why?
|
| Furosemide | 1 | 2011 | 36 | 0.080 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2011 | 28 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 75 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 705 | 0.080 |
Why?
|
| Pyrazines | 2 | 2001 | 79 | 0.080 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 536 | 0.080 |
Why?
|
| Troponin I | 1 | 2011 | 122 | 0.080 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 26 | 0.080 |
Why?
|
| Risk Adjustment | 2 | 2020 | 55 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2011 | 155 | 0.080 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2026 | 172 | 0.080 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 167 | 0.080 |
Why?
|
| Algorithms | 4 | 2020 | 1665 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 275 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 126 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2016 | 707 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3115 | 0.080 |
Why?
|
| Calcium | 1 | 2014 | 1020 | 0.080 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 17 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2026 | 2901 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 37 | 0.070 |
Why?
|
| Drug Evaluation | 2 | 2008 | 101 | 0.070 |
Why?
|
| Exercise | 2 | 2025 | 862 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 108 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 4034 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2010 | 760 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 197 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 271 | 0.070 |
Why?
|
| Oxygen Consumption | 3 | 2013 | 296 | 0.070 |
Why?
|
| Fumarates | 1 | 2007 | 18 | 0.070 |
Why?
|
| Hypothermia | 1 | 2008 | 61 | 0.070 |
Why?
|
| Disease Progression | 2 | 2012 | 2193 | 0.070 |
Why?
|
| Oxidative Stress | 3 | 2020 | 795 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2008 | 81 | 0.070 |
Why?
|
| Amides | 1 | 2007 | 82 | 0.060 |
Why?
|
| Risk Reduction Behavior | 2 | 2019 | 142 | 0.060 |
Why?
|
| Seasons | 1 | 2008 | 333 | 0.060 |
Why?
|
| Mice | 4 | 2026 | 18215 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 831 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2007 | 163 | 0.060 |
Why?
|
| Heart Function Tests | 1 | 2005 | 50 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 442 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 558 | 0.060 |
Why?
|
| Radiometry | 1 | 2025 | 50 | 0.060 |
Why?
|
| Creatinine | 3 | 2012 | 396 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2025 | 98 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2021 | 449 | 0.060 |
Why?
|
| APACHE | 1 | 2005 | 55 | 0.060 |
Why?
|
| Mammary Arteries | 1 | 2005 | 31 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 74 | 0.050 |
Why?
|
| Prednisone | 1 | 2025 | 237 | 0.050 |
Why?
|
| Walking | 2 | 2013 | 227 | 0.050 |
Why?
|
| Vincristine | 1 | 2025 | 188 | 0.050 |
Why?
|
| Adolescent | 4 | 2026 | 20774 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2024 | 59 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2025 | 308 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 39 | 0.050 |
Why?
|
| Young Adult | 3 | 2026 | 10015 | 0.050 |
Why?
|
| Proton Therapy | 1 | 2025 | 155 | 0.050 |
Why?
|
| Survivorship | 1 | 2024 | 46 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 69 | 0.050 |
Why?
|
| Anxiety | 1 | 2010 | 1007 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 76 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 20 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 84 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2025 | 427 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2024 | 134 | 0.050 |
Why?
|
| Exercise Test | 2 | 2015 | 240 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 1 | 2002 | 62 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2024 | 293 | 0.050 |
Why?
|
| Heart Block | 1 | 2022 | 37 | 0.050 |
Why?
|
| Metabolomics | 1 | 2026 | 501 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 137 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2024 | 327 | 0.040 |
Why?
|
| Selection Bias | 1 | 2001 | 18 | 0.040 |
Why?
|
| Health Behavior | 1 | 2005 | 388 | 0.040 |
Why?
|
| Ribose | 1 | 2021 | 12 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2023 | 174 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2018 | 769 | 0.040 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 48 | 0.040 |
Why?
|
| Renin | 2 | 2012 | 75 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 35 | 0.040 |
Why?
|
| Androstenes | 1 | 2021 | 6 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 463 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2001 | 14 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2001 | 33 | 0.040 |
Why?
|
| New York | 1 | 2021 | 69 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2021 | 36 | 0.040 |
Why?
|
| Depression | 1 | 2010 | 1310 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2021 | 67 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 350 | 0.040 |
Why?
|
| Patient Care Team | 2 | 2015 | 559 | 0.040 |
Why?
|
| Feedback | 1 | 2021 | 147 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2026 | 2896 | 0.040 |
Why?
|
| Demography | 1 | 2001 | 237 | 0.040 |
Why?
|
| Cloud Computing | 1 | 2020 | 15 | 0.040 |
Why?
|
| Age Distribution | 1 | 2001 | 423 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2022 | 213 | 0.040 |
Why?
|
| Smartphone | 1 | 2020 | 46 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 522 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 278 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 1158 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 785 | 0.040 |
Why?
|
| Etanercept | 1 | 1999 | 44 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2019 | 11 | 0.040 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2019 | 6 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2015 | 946 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 151 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 410 | 0.040 |
Why?
|
| Diet, Mediterranean | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neurotransmitter Agents | 3 | 2008 | 136 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2026 | 3752 | 0.040 |
Why?
|
| Length of Stay | 1 | 2005 | 1404 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 102 | 0.040 |
Why?
|
| Micronutrients | 1 | 2019 | 61 | 0.040 |
Why?
|
| Porphyrias | 2 | 1988 | 3 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 244 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 623 | 0.030 |
Why?
|
| Sarcopenia | 1 | 2019 | 55 | 0.030 |
Why?
|
| Urea | 1 | 2019 | 219 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 301 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 645 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2026 | 3823 | 0.030 |
Why?
|
| Equipment Design | 1 | 2020 | 536 | 0.030 |
Why?
|
| Dobutamine | 1 | 1998 | 51 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 184 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2019 | 184 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 1572 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1004 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 697 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 79 | 0.030 |
Why?
|
| Protective Factors | 1 | 2018 | 92 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 278 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 2063 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1998 | 113 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 350 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 165 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2019 | 221 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 510 | 0.030 |
Why?
|
| Counseling | 1 | 2019 | 235 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2018 | 124 | 0.030 |
Why?
|
| Alleles | 1 | 2022 | 1675 | 0.030 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 154 | 0.030 |
Why?
|
| Malnutrition | 1 | 2019 | 157 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2026 | 4713 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 229 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 776 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1317 | 0.030 |
Why?
|
| India | 1 | 2016 | 232 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 311 | 0.030 |
Why?
|
| Hyperemia | 1 | 2015 | 30 | 0.030 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 15 | 0.030 |
Why?
|
| Fibrosis | 1 | 1996 | 419 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 69 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 37 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 204 | 0.030 |
Why?
|
| Vasodilation | 1 | 2015 | 175 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2015 | 131 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2015 | 75 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2014 | 72 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 134 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 89 | 0.030 |
Why?
|
| Developing Countries | 1 | 2016 | 301 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 189 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 815 | 0.020 |
Why?
|
| Aldosterone | 1 | 2012 | 58 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2015 | 205 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 69 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2015 | 453 | 0.020 |
Why?
|
| Hemofiltration | 1 | 2012 | 11 | 0.020 |
Why?
|
| Uric Acid | 1 | 2012 | 110 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 242 | 0.020 |
Why?
|
| Gout | 1 | 2015 | 170 | 0.020 |
Why?
|
| Models, Structural | 1 | 2011 | 34 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4478 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 58 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 371 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 237 | 0.020 |
Why?
|
| Systole | 1 | 2011 | 195 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 7403 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 178 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 631 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 303 | 0.020 |
Why?
|
| Dyspnea | 1 | 2011 | 159 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Potassium | 1 | 2010 | 265 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 724 | 0.020 |
Why?
|
| Fatigue | 1 | 2010 | 192 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 175 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 412 | 0.020 |
Why?
|
| Caregivers | 1 | 2015 | 577 | 0.020 |
Why?
|
| Nifedipine | 1 | 1988 | 22 | 0.020 |
Why?
|
| Clonidine | 1 | 1988 | 30 | 0.020 |
Why?
|
| Ranitidine | 1 | 1988 | 31 | 0.020 |
Why?
|
| Autonomic Agents | 1 | 2008 | 3 | 0.020 |
Why?
|
| Selenoproteins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2008 | 23 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 6093 | 0.020 |
Why?
|
| Body Temperature | 1 | 2008 | 126 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2008 | 99 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1478 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 1988 | 149 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 564 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 320 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2008 | 182 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 227 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 484 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 903 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1877 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3797 | 0.010 |
Why?
|
| Antioxidants | 1 | 2008 | 335 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1988 | 378 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2011 | 821 | 0.010 |
Why?
|
| Child | 1 | 2024 | 26175 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2003 | 148 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 424 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 576 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 686 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2001 | 189 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 1997 | 40 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 417 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1998 | 244 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1998 | 591 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 2333 | 0.010 |
Why?
|